Nektar Therapeutics’ (NKTR) “Market Perform” Rating Reaffirmed at William Blair
William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...
BTIG Remains a Buy on Nektar Therapeutics (NKTR)
BTIG analyst Julian Harrison reiterated a Buy rating on Nektar Therapeutics (NKTR – Research Report) today and set a price target of $4.00. The ...
William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)
In a report released today, Andy Hsieh from William Blair maintained a Hold rating on Nektar Therapeutics (NKTR – Research Report). The ...
Nektar Therapeutics: Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
TrialNet to conduct the Phase 2 randomized, placebo-controlled clinical study -- SAN FRANCISCO and NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Nektar Therapeutics ...
Le Lézard2d
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
Nektar Therapeutics today announced that it will host a virtual investor and analyst event with Type 1 Diabetes (T1D) Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m.
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
Nektar Therapeutics (Nasdaq: NKTR) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's ...
Diffuse Large B-Cell Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...
Healio9d
Rezpegaldesleukin gets FDA fast track designation for atopic dermatitis
The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...